DEERFIELD, IL — April 19, 2002 — Results from the largest randomized controlled trial ever conducted among patients undergoing peritoneal dialysis (PD) demonstrate that PD, a flexible home-based dialysis therapy for people with end-stage renal disease (ESRD), may be a viable option for a greater range of patients and existing patients may be able to remain on therapy longer than would have been assumed from current practice guidelines.
It is estimated that more than one million people worldwide suffering from ESRD are treated with some form of dialysis therapy, 10 to 15 percent of whom rely on a flexible daily PD regimen. The study, conducted by leading researchers in Mexico under the auspices of the Mexican health-care authorities , and supported by Baxter Healthcare Corporation and its Mexico affiliate, appears in the May issue (Volume 13, Issue 5) of the peer-reviewed publication, Journal of the American Society of Nephrology (JASN).
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!